Brielle Urciuoli

Eric Whitman, MD, discusses data for pembrolizumab in the frontline treatment of advanced melanoma and ongoing research with the agent in other settings of the disease.

A recent warning issued by the FDA advised that breast implants may increase an individual’s risk of developing anaplastic large cell lymphoma.

Kathleen N. Moore, MD, discusses the use of PARP inhibitors such as niraparib for the treatment of ovarian cancer – advances that could be practice changing, she says.

Helmut Schaider, MD, discusses why drug resistance in melanoma may be due to epigenetic changes and not mutation-induced changes, as well as the role of immunotherapy/targeted therapy combinations in combating resistance.

Patients with relapsed, platinum-sensitive, high-grade, ovarian cancer saw activity with the PARP inhibitor rucaparib, according to findings from the ARIEL2 study presented at the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland. 

Dabrafenib combined with trametinib continued to demonstrate durable efficacy for patients with <em>BRAF</em> V600E/K-mutant melanoma.

Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab have demonstrated that the combination was well-tolerated with no dose-limiting toxicities in early-stage melanoma.

PD-L1 expression is starting to be part of the standard of care in determining the appropriate treatment plan for newly diagnosed non-small cell lung cancer. However, testing for the biomarker is not always necessary for patients who have relapsed or who have small cell lung cancer.

With anaplastic thyroid cancer (ATC) being a rare disease that often has poor prognoses, researchers are seeking therapies for these patients that are more promising than surgery or radiation.

In an interview with <em>Targeted Oncology</em>, Naiyer Rizvi, MD, director of Thoracic Oncology and Immunotherapy at Columbia University Medical Center, discusses data from the&nbsp;phase III KEYNOTE-024 trial and expressed his optimism about immunotherapy in the NSCLC field.

Since its approval 5 years ago, ruxolitinib (Jakafi) continues to drastically change the treatment landscape and quality of life of patients with myeloproliferative neoplasms (MPNs), including a subset of patients with the bone marrow neoplasm, polycythemia vera (PV).

It&#39;s been an exciting year thus far for patients with neuroendocrine tumors, with the FDA approving a new treatment regimen and more advancements on the horizon.

Nintedanib may be a promising treatment option for patients with metastatic colorectal cancer who are not responding to treatment.

The United States Preventative Services Task Force (USPSTF) has updated its 2008 recommendation for colorectal cancer (CRC) screening to include 7 CRC screening tests for average-risk, asymptomatic adults between the ages of 50 and 75 to reduce the risk of CRC mortality.

Drinking alcohol, eating processed meat, and being overweight can each increase an individual's chance of developing stomach cancer.